UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Classic psychedelics, health behavior, and physical health
Psychological insight during a classic psychedelic experience may lead to positive health behavior change and better physical health.
Therapeutic use of psilocybin: Practical considerations for dosing and administration
Our goal is to increase the knowledge and comfort of health care professionals to discuss and counsel their patients on psilocybin therapy.
Lower-dose psycholytic therapy – A neglected approach
The article provides comprehensive background information and outlines the essential features of psycholytic therapy.
Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial
Using a patient-informed regimen, we conducted an exploratory randomized, double-blind, placebo-controlled study to systematically investigate the effects of psilocybin in cluster headache.
MAPS PBC completes second phase 3 “MAPP2” trial of MDMA-assisted therapy for treatment of PTSD
The top-line results are expected in the first quarter of 2023.
Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability
Despite the methodological limitations, we conclude that from a clinical view, maintenance ketamine treatment seems to be of therapeutic potential.
Psilocybin mushrooms for psychological and existential distress: Treatment for a patient with palliative lung cancer
This experience led to immediate, substantial, and sustained improvements in her distress and quality of life.
Body mass index (BMI) does not predict responses to psilocybin
These findings have important implications for the standardization of a fixed therapeutic dose in psychedelic-assisted therapy.
Self-transcendent experiences as promoters of ecological wellbeing? Exploration of the evidence and hypotheses to be tested
We explore the emerging potential of a type of mental state known as self-transcendent experiences (STEs) as a driver of ecological wellbeing.
Dose-response relationships of LSD-induced subjective experiences in humans
Here we present the first meta-analysis establishing dose-response relationship estimates of the phenomenological states induced by LSD.
Ayahuasca's therapeutic potential: What we know – and what not
Overall, evidence for depression and SUD is more consistent, with numerous and diverse studies.
Introduction to the symposium on psychedelics and psychoanalysis: A conversation long overdue
The essay explores how neuroscience research on psychedelics suggests applications for psychotherapy
MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder
Chronic pain scores among medium and high pain subgroups were significantly lower following MDMA-AT.
Serotonergic antidepressant use is associated with weaker psilocybin effects
Serotonergic antidepressants appear to weaken psilocybin’s effects relative to a nonserotonergic antidepressant.
Single-dose psilocybin for a treatment-resistant episode of major depression
In ... participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly ... over a period of 3 weeks.